Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology
Disease Category: Gastroesophageal Reflux Disease (GERD)
Trial Information
A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to compare Rabeprazole Extended-Release (ER) 50 mg to Esomeprazole 40 mg and see how effective they are in healing erosions of the esophagus and providing symptom relief after 4 or 8 weeks of treatment.
Patient Inclusion Criteria:
- Have had GERD symptoms for the past 3 months
- Are between the ages of 18 and 75
- Are willing and able to complete a daily diary
Patient Exclusion Criteria:
- Unstable diabetes
- Diagnosis of Inflammatory Bowel Disease
- Required use of daily anti-inflammatory drugs, oral steroids, or asprin
Carolinas Research Associates
4315 Physicians Blvd.
Harrisburg, NC 28075
Fax: 704-364-4422
EMail: contact@carolinasresearch.com
View Google Map
Research Center Information: Carolinas Research Associates
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
